The aim of this study is to evaluate the effectiveness of a patient managing their own insulin adjustment (using a schedule) compared to when a doctor manages the insulin adjustment. The study drug Toujeo will be administered once a day by subcutaneous injection.
What does it involve?
Before taking part in the study a full medical history and examination must be taken to ensure that it is safe for you to take part.
The study will consist of 3 periods and 16 visits (6 clinic visits and 10 phone call visits)
Period 1: the 2-week screening period
Period 2: the 24-week open-label treatment period
Period 3: a safety follow-up period
Overall the duration of the study for each patient is approximately 28 weeks.
- Patients with Type 2 diabetes diagnosed for at least 1 year at the time of screening
- Treated with ≥1 non-insulin antihyperglycemic drug(s) with or without a basal insulin, for at least 6 months.
To refer potential participants or to request further information, please contact the research team:
Tel: 023 7047 5258